## ADUS: Addus HomeCare Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.08 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($113.50)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $120 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-1.1%)
- Vanguard Group Inc: 7.0% (+2.9%)
- Capital Research Glo: 6.5% (+9.0%)
- Wasatch Advisors LP: 5.1% (+0.8%)
- Silvercrest Asset Ma: 4.6% (+14.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +1.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.08 suggests fair value with growth premium. Balance sheet: low leverage (D/E 0.36). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.94 |
| 52W Range | $88.96 - $136.72 |
| Short Interest | 4.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.08 |
| Forward P/E | 17.6 |
| Current P/E | 19.6 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.9% to 4.7% (+1.8% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 0.4% confirms short-term momentum alignment. AM_20 at 5.8% shows strong absolute momentum above own 20MA. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.24), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.70% (CS: 88) | Strong |
| RSI_14 | 60.9 | Neutral |
| MACD Histogram | 1.24 | Bullish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 1.104x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $120.84
- **Stop Loss:** $113.50 (6.1% risk)
- **Target:** $135.52 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $12,325.68
- **Portfolio %:** 12.33%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-23 (Est: $1.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.53 | $1.56 | +1.7% |
| 2025Q2 | $1.46 | $1.49 | +1.8% |
| 2025Q1 | $1.33 | $1.42 | +6.5% |
| 2024Q4 | $1.36 | $1.38 | +1.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*